JD Capital-invested Fushine Floated on GEM

2015-12-23

In recent days, JD Capital-invested Jiangxi Fushine Pharmaceutical Co., Ltd (300497) officially entered the Growth Enterprises Market (GEM) and held its Initial Public Offering (IPO). The 18 million shares outstanding for Fushine’s IPO totaled 72 million yuan at 15.33 yuan per share. CXj九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

Fushine, founded in 2002, is an innovative pharmaceutical company specializing in the R&D, manufacturing, sales and service of pharmaceutical intermediates. The company is a “National High-Technology Enterprise”and “Excellent Enterprise in Jiangxi Province”, and owns a “Provincial Enterprise Technology Center”. It holds multiple national patents and has more than ten key new products on provincial level and advanced technology products. The company is currently the world’s biggest API manufacturer of β-lactamase inhibitors, and also the leading supplier of Carbapenem intermediates. It presses home its advantages in production technology, quality management, EHS management and customer services, and sells its products to more than ten countries and regions worldwide. CXj九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

With the global economic development, demographic increase and population aging, the global demand for pharmaceutical products is on the rise and the pharmaceutical market continues to grow. According to IMS, an authoritative international pharmaceutical consulting organization, emerging pharmaceutical market grew at a rate ranging from 14% to 17% from 2010 to 2014. China, the world’s largest emerging pharmaceutical market, will become the second largest pharmaceutical market following second only to the US in 2020, with its market share up from 3% to 7.5%.CXj九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

In the future, constraints imposed by the external environment and resources shortage will worsen, therefore the combination of technology innovation and upgrading will become the key to the restructuring of pharmaceutical industry. Meanwhile, continuous improvement in innovation, R&D and industrialization will become a main competitive edge and a new source for profit increase.CXj九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

JD Capital became a shareholder of Fushine in 2012, holding 5.56% of its shares before its IPO.CXj九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

Up to the present, nearly 50 of JD Capital’s investees have been listed on the National Equities Exchange and Quotations (NEEQ). In 2015 alone, JD Capital helped eight of them successfully enter the A-share market. CXj九鼎投资(600053.SH)_上交所私募股权投资领域上市公司


CXj九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

EN | CN